Latest News and Press Releases

Austin, TX, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product...

Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...

Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...

Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 ...

Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in...

SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...

Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...

Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...

SALT LAKE CITY, UT--(Marketwired - May 10, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announces they are embarking on a new investigational study applying...

SALT LAKE CITY, UT--(Marketwired - January 26, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device company which explores and develops medical applications of new technologies in the...